Research-literacy siteEducational evidence reviews only — not medical advice, not dosing guidance, not a protocol for human or animal use. Medical disclaimer.

PeptideStacks

Prescription-Only Medicine Advertising Rules (UK)

It is a criminal offence in the UK to advertise a prescription-only medicine to the general public. This page explains why, and why PeptideStacks avoids any framing that could read as promotional.

Educational research-literacy content only. Not medical advice, not dosing guidance, not sourcing advice, and not a protocol for human or animal use. See our responsible information policy.

The rule

Under the Human Medicines Regulations 2012 (in particular Regulation 279, restricting advertisement of POMs to the general public), it is unlawful to issue most public-facing advertisements for prescription-only medicines (POMs). The MHRA enforces this in practice through the Blue Guide: Advertising and Promotion of Medicines in the UK. The ASA / CAP Code is the parallel self-regulatory framework that addresses much of the same conduct in consumer media.

Why the rule exists

Prescription medicines are restricted to prescription supply because a clinician’s judgement is required to assess suitability, dose, and risk. Public-facing advertising could short-circuit that judgement, drive inappropriate demand, or lead to off-label or counterfeit use.

Where this bites for peptides

  • GLP-1 agonists — semaglutide (Wegovy / Ozempic), tirzepatide (Mounjaro), and trial-stage compounds such as retatrutide are POMs for the relevant indications. The MHRA has taken public enforcement action against UK weight-loss advertising of these compounds. See: weight-loss advertising caution.
  • PT-141 / bremelanotide — approved as Vyleesi in the US for hypoactive sexual desire disorder in pre-menopausal women; not currently authorised in the UK. Public-facing UK advertising would engage POM rules.
  • Any peptide marketed with medicinal claims — even where unapproved, can be drawn into medicines law by virtue of the presentation. See: UK peptide law explained.

Why our content reads the way it does

We do not write “best for weight loss,” “recommended dose,” or before/after framing. We do not use promotional language. Where we discuss compounds that are prescription medicines elsewhere in the world, we describe the trial evidence and regulatory status — we do not direct readers to obtain the compound.

If you are considering a GLP-1 medicine

Speak to a registered clinician. Licensed prescribing routes exist for the appropriate indications. PeptideStacks is not a substitute for a prescriber and does not provide acquisition advice.